XR 303

Drug Profile

XR 303

Alternative Names: Anti-CEA sheep monoclonal antibody - KS Biomedix Holdings; Anti-CEA sheep monoclonal antibody 6H9; KAb201; KS 6H9Chi; KSB 303; KSB-303C; KSB-303P; Sheep anti-CEA monoclonal antibody - KS Biomedix Holdings; SMA CEA - KS Biomedix Holdings; XR303

Latest Information Update: 13 Sep 2010

Price : $50

At a glance

  • Originator Cancer Research UK; Xenova Group
  • Developer Celtic Pharma
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 13 Sep 2010 Discontinued - Phase-I for Colorectal cancer in Malaysia (Parenteral)
  • 13 Sep 2010 Discontinued - Phase-I/II for Pancreatic cancer in Europe (Parenteral)
  • 08 Aug 2007 XR 303 is still in phase I/II trials for Pancreatic cancer in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top